Viking Global has co-led a $299.2M financing round for BridgeBio with KKR. Other existing investors including Perceptive Advisors, AIG, Aisling Capital, Cormorant Capital and Hercules Capital participated. BridgeBio, a clinical-stage biopharmaceutical company focused on genetically targeted therapies, was founded in 2015 and had previously raised $149M. The company will use the fresh capital to support its existing research and development programs as well as expand its efforts to rapidly develop new medicines.

BridgeBio’s co-founder and CEO Neil Kumar, Ph.D. said in the financing announcement, “We are privileged to be working with investors who believe in our goal of creating medicines for patients with genetic disease. We are aware that many of these patients lack effective treatment options, and we take our mission to help them seriously. The path from promising early stage science to a drug that makes a difference for patients requires long-term vision and steady commitment. We are fortunate to have our investors’ support as we develop these treatments.”

The Gunderson deal team was led by Greg Volkmar with Mark Foster and Jorge Solis.